Lacutamab

Lacutamab (IPH4102) is Innate Pharma's lead wholly-owned asset, a humanized antibody that binds KIR3DL2, a surface protein aberrantly expressed on cancerous T cells in Sézary syndrome and a fraction of peripheral T-cell lymphomas (PTCL) [1]. Sézary syndrome is a rare, aggressive blood cancer with a skin-tropic presentation: patients develop red, thickened, often disfiguring rashes over most of their body as malignant T cells accumulate in skin, blood, and lymph nodes, with median survival on standard therapy under three years and near-universal relapse. The Phase 2 TELLOMAK program (NCT03902184) tested lacutamab as monotherapy in relapsed/refractory cutaneous T-cell lymphoma cohorts (Sézary and mycosis fungoides) and in combination with gemcitabine plus oxaliplatin (GemOx, a standard salvage chemotherapy backbone) for PTCL, closing enrollment at 170 patients [3]. Final Sézary data (October 2024 cutoff, presented at ASCO 2025) showed an objective response rate of 42.9% with median duration of response of 25.6 months and median progression-free survival of 8.3 months in a heavily pretreated post-mogamulizumab population [8]. On February 17, 2025 the FDA granted Breakthrough Therapy Designation for relapsed/refractory Sézary syndrome after at least two prior systemic therapies including mogamulizumab, based on those TELLOMAK results [6]. FDA has cleared the protocol for a confirmatory Phase 3 (TELLOMAK 3) in cutaneous T-cell lymphoma; launch has been guided to H2 2026 and is explicitly contingent on non-dilutive financing or a pharma partnership [7]. The commercial thesis is not a blockbuster, it is an orphan cutaneous lymphoma franchise with strong regulatory tailwinds and optionality in PTCL if KIR3DL2 patient selection works. BLA (Biologics License Application) is the formal marketing application filed with FDA to request approval of a biologic drug.

Novel biologic, never approved in any indication or geography, but with a stack of regulatory designations that is now unusually strong. FDA granted orphan drug designation for cutaneous T-cell lymphoma, Fast Track designation for relapsed/refractory Sézary syndrome (2019), and Breakthrough Therapy Designation (February 17, 2025) for relapsed/refractory Sézary syndrome after at least two prior systemic therapies including mogamulizumab [6]. The BTD was granted on the strength of the 42.9% Sézary ORR with 25.6-month median duration of response from TELLOMAK [8], and it is the single most important regulatory event in the program's history. Breakthrough designations historically correlate with meaningfully higher Phase 2-to-approval conversion rates in oncology, both because FDA has already signaled that the data package is credible and because it unlocks intensive regulatory interaction on the BLA. EMA granted PRIME designation in 2020 for Sézary syndrome, the European analogue of Breakthrough, meaning the European regulatory pathway has similar structural support [6]. FDA placed a partial clinical hold on the lacutamab IND on October 5, 2023 after a fatal case of hemophagocytic lymphohistiocytosis (HLH) in TELLOMAK; the hold was lifted after the death was adjudicated as unrelated to lacutamab [9]. The current status is that TELLOMAK Phase 2 has read out (final Sézary and mycosis fungoides data at ASCO 2025), FDA has cleared the TELLOMAK 3 confirmatory Phase 3 protocol, and Innate is seeking a partnership or non-dilutive financing to fund the Phase 3 launch, guided to H2 2026 [7]. The regulatory question has effectively been decided in Innate's favor. The investment question is financing.

KIR3DL2 (also called CD158k) is a receptor on a small subset of NK cells and T cells that normally acts like a brake, telling those immune cells to stand down when they encounter certain HLA class I signals on healthy cells. Its expression on normal circulating T cells is near-zero. In Sézary syndrome, a leukemic form of cutaneous T-cell lymphoma, malignant T cells express KIR3DL2 at very high density on essentially every tumor cell. That density gradient between tumor and normal tissue is exactly what a targeted antibody wants, a large signal-to-noise ratio. Lacutamab is an Fc-engineered humanized IgG1 that binds KIR3DL2 on tumor cells and recruits natural killer cells and macrophages to destroy them through antibody-dependent cellular cytotoxicity (ADCC), the same killing mechanism rituximab uses against CD20 on B-cell lymphomas, a well-validated modality with two decades of clinical proof [1]. Notably, the ASCO 2025 subgroup analysis showed anti-tumor activity in both KIR3DL2-high (≥1%) and KIR3DL2-low (<1%) mycosis fungoides patients at baseline, suggesting ADCC engagement is efficient at low target densities and that a KIR3DL2 immunohistochemistry cutoff may not cleanly stratify responders [8]. The biological case for KIR3DL2 as a target rests on histopathology rather than a driver mutation. KIR3DL2 does not appear to be a growth signal the tumor requires, it is a surface marker that happens to be tumor-selective. That is important commercially, meaning lacutamab is not a signaling inhibitor with a resistance liability, it is a targeting antibody whose success depends on target expression and immune-effector function in the patient. Cheminant and colleagues extended this thesis in 2022, showing KIR3DL2 is also expressed on adult T-cell leukemia cells [2], suggesting applications beyond CTCL if development priorities allow.

TELLOMAK (NCT03902184) is a Phase 2, open-label, multi-cohort study that closed enrollment at 170 patients [3]. Cohort 1 is Sézary syndrome monotherapy in patients with at least two prior systemic therapies including mogamulizumab (63 patients as of the October 2024 cutoff). Cohort 2 is mycosis fungoides monotherapy. Cohort 3 is KIR3DL2-expressing PTCL in combination with gemcitabine and oxaliplatin (GemOx, a standard salvage chemotherapy doublet). Primary endpoint is investigator-assessed objective response rate using consensus global response scoring for CTCL cohorts, with no comparator arm. Single-arm ORR is the read. Final ASCO 2025 results reported Sézary global ORR 42.9%, median duration of response 25.6 months, median PFS 8.3 months, and MF global ORR 19.6% [8]. Safety: Grade ≥3 related treatment-emergent adverse events in 20.6% of patients, related serious adverse events in 9.5%, and related adverse events leading to discontinuation in 6.3% [8]. The design is defensible for an orphan indication where randomized trials are difficult, and the 42.9% Sézary ORR combined with a 25.6-month duration of response is the specific combination that has historically supported CTCL accelerated approvals (mogamulizumab's registrational trial used comparable single-arm-adjacent data). NCT04984837 is a separate Phase 2 run by the Lymphoma Academic Research Organisation (LYSA), a French cooperative group, in 49 patients with relapsed/refractory PTCL selected for KIR3DL2 expression [4]. Primary endpoint is median modified progression-free survival (mPFS, a PFS variant that uses modified censoring rules to reduce dropout bias) assessed by CT. This is a smaller, biomarker-selected trial that tests whether patient selection materially improves the PTCL signal. NCT05321147 was a completed 20-patient Phase 1 in KIR3DL2-expressing R/R PTCL, primarily safety and dose-finding [5]. TELLOMAK 3 is the FDA-cleared confirmatory Phase 3 in cutaneous T-cell lymphoma, guided to launch H2 2026 subject to financing [7]. Enrollment risk on the Phase 2 is zero (both trials closed or in follow-up). The remaining Phase 2 design concerns are heterogeneity across the three TELLOMAK cohorts and the fact that ORR in Sézary requires composite scoring across blood, skin, lymph node, and viscera compartments.

Our model estimates a 17% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 21%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Financing risk has overtaken regulatory risk as the dominant failure mode. Innate reported €25.4M cash as of March 31, 2026, with runway guided through Q3 2026 [7]. TELLOMAK 3 Phase 3 launch (guided H2 2026) is explicitly contingent on non-dilutive financing, meaning a pharma partnership or royalty deal. If a partnership does not materialize before the cash runway expires, the company faces a dilutive equity raise into a distressed situation or must delay TELLOMAK 3, either of which would compress equity value even with the strong regulatory package. Efficacy risk in Sézary is largely resolved by the 42.9% ORR and 25.6-month DOR readout. Efficacy risk in PTCL remains, awaiting the LYSA-sponsored NCT04984837 readout. If the KIR3DL2 IHC cutoff does not correlate with response in PTCL, the biomarker fails and PTCL becomes hard to develop commercially, though the ASCO 2025 MF subgroup data hint that ADCC works below the 1% cutoff, which is either encouraging (broader eligible population) or discouraging (biomarker not discriminating) depending on interpretation [8]. Safety risk includes the historical partial clinical hold (October 2023) triggered by a fatal HLH case that was ultimately adjudicated as unrelated to lacutamab [9]; the hold was lifted, but HLH is a serious immune-activation syndrome and any recurrence in TELLOMAK 3 would draw immediate FDA scrutiny. KIR3DL2 is also expressed on a minority of normal NK cells, so depleting those cells could theoretically compromise anti-viral surveillance; TELLOMAK long-term follow-up has not shown dose-limiting immunosuppression to date. Regulatory risk is materially lower than previously modeled because BTD has been granted; FDA has effectively signaled that the accelerated approval pathway is viable pending confirmatory Phase 3. Commercial risk is meaningful even on approval. US Sézary syndrome incidence is approximately 270-300 new cases per year (0.8-0.9 per million annually), one of the rarest indications in hematologic oncology, and pricing power is constrained by mogamulizumab and brentuximab vedotin in adjacent indications. A partnership or acquisition is the near-certain commercial path, not independent launch, and the financing situation makes Innate a motivated seller.

The regulatory question has been answered. The financing question has not. The Sézary Phase 2 read is done and it cleared: 42.9% ORR with 25.6-month median duration of response is above the historical CTCL accelerated approval bar, and FDA granted BTD on the strength of that data [6][8]. TELLOMAK 3 Phase 3 protocol is FDA-cleared, launch guided to H2 2026 [7]. The catalyst that now matters most for equity value is a TELLOMAK 3 partnership announcement, because Innate's own cash runway ends in Q3 2026 and the Phase 3 will not launch without external funding. A partner acquires a BTD-designated asset with a cleared Phase 3 protocol in an orphan indication with weak competition, which is a fundable structure, but the clock is short and the negotiating leverage tilts toward the partner. Between now and any deal, secondary catalysts are the LYSA PTCL readout (NCT04984837, KIR3DL2-selected, mPFS primary) [4] and any TELLOMAK 3 enrollment announcement. Below a partnership, this is likely a distressed financing story. With one, it is a plausible orphan drug franchise with a clear regulatory path. Innate Pharma trades as IPH on Euronext Paris and IPHA on Nasdaq. Between readouts, the news that matters is partnership announcements, financing runway extension, and TELLOMAK 3 enrollment start. Investors should not build models on the difference between 900 and 300 US Sézary cases per year, the actual number is ~270-300 (0.8-0.9 per million annually) and peak sales assumptions above roughly $400M annually in Sézary alone require aggressive market penetration and pricing.